Yingchang Mi

Prof. Dr. Yingchang Mi


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HWHui Wei
Hui Wei
YWYing Wang
Ying Wang
RGRobert Peter Gale
Robert Peter Gale
DLDong Lin
Dong Lin
CZChunlin Zhou
Chunlin Zhou
JWJIANXIANG WANG
JIANXIANG WANG
Purpose: Cytarabine, 100-200 mg/mE+2/d, is commonly-used in induction therapy of acute myeloid leukaemia (AML). Whether a higher dose of cytarabine would be more effective is unknown. Also, there is controversy whether high-dose cytarabine is better than an intermediate-dose combined with other drugs for post-remission therapy. In this open-label, randomized, parallel controlled group study, roles of intermediate-dose cytarabine were investigated. Subjects and Methods: Subjects with AML age 15-55 years were randomized to receive daunorubicin, omacetaxine mepesuccinate and conventional- or intermediate-dose cytarabine. Subjects achieving complete remission were randomized to receive 3 courses of high-dose cytarabine or 2 courses of intermediate-dose cytarabine with daunorubicin in the 1st and mitoxantrone in the 2nd course. The primary endpoint was disease-free survival (DFS). Results: 591 subjects were randomized to intermediate- (N=295) or conventional-dose (N=296) cytarabine group. Three-year DFSs were 67% (95% confidence interval [CI], 61-73) in the intermediate-dose cohort compared with 54% (95%CI, 48-61) in the conventional-dose cohort (Hazard Ratio [HR]=0.67; 95%CI, 0.51-0.89; P=0.005). Three-year survivals were 68% (95%CI, 63-74) and 59% (95%CI, 53-65; HR=0.720 95%CI, 0.56-0.94; P=0.014). Two course of intermediate-dose cytarabine with daunorubicin or mitoxantrone resulted in similar DFS and survival as three course of high-dose cytarabine when used for post-remission therapy. Conclusions: Induction therapy with intermediate-dose cytarabine with daunorubicin and omacetaxine mepesuccinate increases DFS and survival in persons with AML age 15-55 years compared with conventional-dose cytarabine.

1 September 2013 in Leukemia Research
Verified
Journal Article
Closed access
SWShuning Wei
Shuning Wei
SWSiping Wang
Siping Wang
SQShaowei Qiu
Shaowei Qiu
JQJunyuan Qi
Junyuan Qi
YMYingchang Mi
Yingchang Mi
JWJIANXIANG WANG
JIANXIANG WANG

11 November 2022 in Blood Science
Verified
Journal Article
Open access
QHQishan Hao
Qishan Hao
YSYang Song
Yang Song
QFQiuyun Fang
Qiuyun Fang
YLYani Lin
Yani Lin
LCLong Chen
Long Chen
YMYingchang Mi
Yingchang Mi
Methotrexate (MTX) has an antitumor effect when used for the treatment of acute lymphoblastic leukemia (ALL). This study aims at evaluating the associations between 14 polymorphisms of six genes involved in MTX metabolism with serum MTX concentration and toxicity accompanying high-dose MTX. Polymorphisms in 183 Chinese patients with ALL were analyzed using TaqMan single nucleotide polymorphism genotyping assay. The serum MTX concentration was determined using homogeneous enzyme immunoassay. MTX-related toxicities were also evaluated. Renal toxicity was significantly associated with higher serum MTX concentrations at 24, 48, and 72 hours, and MTX elimination delay (P = 0.001, P < 0.001, P < 0.001, and P < 0.001, respectively), whereas SLCO1B1 rs4149056 was associated with serum MTX concentrations at 48 and 72 hours, and MTX elimination delay in candidate polymorphisms (P = 0.014, P = 0.019, and P = 0.007, respectively). SLC19A1 rs2838958 and rs3788200 were associated with serum MTX concentrations at 24 hours (P = 0.016, P = 0.043, respectively). MTRR rs1801394 was associated with serum MTX concentrations at 72 hours (P = 0.045). Neutropenia was related to SLC19A1 rs4149056 (odds ratio [OR]: 3.172, 95% confidence interval [CI]: 1.310–7.681, P = 0.011). Hepatotoxicity was associated with ABCC2 rs2273697 (OR: 3.494, 95% CI: 1.236–9.873, P = 0.018) and MTRR rs1801394 (OR: 0.231, 95% CI: 0.084–0.632, P = 0.004). Polymorphisms of SLCO1B1, SLC19A1, ABCC2, and MTRR genes help predict higher risk of increased MTX levels or MTX-related toxicities in adult ALL patients.

10 February 2025 in Molecular Oncology
Verified
Journal Article
Open access
YSYang Song
Yang Song
ZWZhe Wang
Zhe Wang
GZGuangji Zhang
Guangji Zhang
JHJiangxue Hou
Jiangxue Hou
KLKaiqi Liu
Kaiqi Liu
YMYingchang Mi
Yingchang Mi
Acute myeloid leukemia (AML) is a heterogeneous cancer, making outcomes prediction challenging. Several predictive and prognostic models are used but have considerable inaccuracy at individual level. We tried to increase prediction accuracy using a multi‐omics strategy. We interrogated data from 1391 consecutive, newly diagnosed subjects with AML, integrating information on mutation topography, DNA methylation, and transcriptomics. We developed an unsupervised multi‐omics classification system (UAMOCS) with these data. UAMOCS provides a multidimensional understanding of AML heterogeneity and stratifies subjects into three cohorts: (a) UAMOCS1 [high lymphocyte activating 3 (LAG3) expression, chromosome instability, myelodysplasia‐related mutations]; (b) UAMOCS2 (monocytic‐like profile, immune suppression and activated angiogenesis and hypoxia pathways); and (c) UAMOCS3 [CCAAT enhancer binding protein alpha (CEBPA) mutations and MYC pathway activation]. UAMOCS distinguishes overall survival rates across the cohorts (TCGA P = 0.042; GSE71014 P = 0.043; ihCAMs‐AML, GSE102691 and GSE37642 all P < 0.001). The model's C‐statistic is comparable to the 2022 ELN risk classification (0.87 vs 0.82; P = 0.162), but offers a more nuanced distinction between intermediate‐ and high‐risk groups. When combined with high‐throughput drug sensitivity testing, UAMOCS can accurately predict sensitivity to azacitidine (AZA) and venetoclax. The UAMOCS system is available as an R package. The UAMOCS system has the potential to redefine AML subtypes, enhance prognostic predictions, and guide treatment strategies based on patients' immune status and expected responses to therapies.

11 May 2022 in Hematology
Verified
Journal Article
Open access
YSYang Song
Yang Song
JHJiangxue Hou
Jiangxue Hou
LWLi Wan
Li Wan
KLKaiqi Liu
Kaiqi Liu
CZChunlin Zhou
Chunlin Zhou
YMYingchang Mi
Yingchang Mi
Resembling acute promyelocytic leukemia (APL) is a unique subtype of APL who sharing clinical, morphological, and immunophenotypic features with typical APL, but lacking evidence of PML-RARA fusion...

17 May 2022 in Blood Science
Verified
Journal Article
Open access
GZGuangji Zhang
Guangji Zhang
YSYang Song
Yang Song
LWLi Wan
Li Wan
KLKaiqi Liu
Kaiqi Liu
SQShaowei Qiu
Shaowei Qiu
YMYingchang Mi
Yingchang Mi
Introduction: Acute promyelocytic leukemia (APL) is mostly due to the chromosome translocation t (15; 17) (q22; q12), leading to the formation of PML-RARA fusion protein. Some patients carried rare translocation involving RARA gene, who were called variant APL caused by RAR family (RARA, RARB, and RARG) and partner genes. STAT5b-RARA was a rare type of molecular genetic abnormality with unfavorable prognosis which have been reported in only 18 cases in variant APL. Knowledge of STAT5b-RARA (+) APL treatment is still limited. Case report: We presented a 38-year-old female variant APL case, who was STAT5b-RARA positive detected by reverse transcription polymerase chain reaction. The patient failed to respond after four-drug combined induction chemotherapy: idarubicin, cytarabine, all trans retinoic acid, and arsenic trioxide (As2O3). Then, the patient was re-induced with azacytidine, but still failed to achieve complete remission (CR). Next, she was treated with Venetoclax combining with homoharringtonine and cytarabine as the salvage therapy and achieved CR. Later, the patient received hematopoietic stem cell transplantation after 4 cycles of consolidation therapy. Conclusion: Venetoclax combining with homoharringtonine and cytarabine has been used as the salvage therapy in the STAT5b-RARA positive APL successfully.